Overview
The IASLC Education Committee presents a one-hour live session focused on the review and discussion of the most impactful and important topics presented at the 2025 IASLC North American Conference on Lung Cancer (NACLC) meeting.
- Interpret emerging evidence comparing segmentectomy and lobectomy, including implications for surgical decision-making and lymph node assessment.
- Describe the role of family history as a risk factor for lung cancer among women and individuals with low smoking exposure.
- Evaluate updated efficacy and safety data for zenocutuzumab in treatment-naïve patients with advanced NRG1 fusion–positive NSCLC, and assess its potential role in targeted treatment strategies.
- Hari Keshava – OA01.06: Segmentectomy Achieves Non-Inferior Survival Outcomes Compared to Lobectomy in Peripheral ≤3 cm Non-Small Cell Lung Cancer With Occult Lymph Node.
- Sulin Wu – OA01.03: Uncovering Hidden Risk: The Role of Family History in Lung Cancer Among Women and Low-Exposure Smokers.
- Stephen Liu – OA01.02: Efficacy and safety of zenocutuzumab, a HER2/HER3 bispecific antibody, in treatment-naive, advanced NRG1+ NSCLC: Updated analysis from the ongoing phase 2 eNRGy trial.
The IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
IASLC designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Interpret emerging evidence comparing segmentectomy and lobectomy, including implications for surgical decision-making and lymph node assessment.
- Describe the role of family history as a risk factor for lung cancer among women and individuals with low smoking exposure.
- Evaluate updated efficacy and safety data for zenocutuzumab in treatment-naïve patients with advanced NRG1 fusion–positive NSCLC, and assess its potential role in targeted treatment strategies.
- Hari Keshava – OA01.06: Segmentectomy Achieves Non-Inferior Survival Outcomes Compared to Lobectomy in Peripheral ≤3 cm Non-Small Cell Lung Cancer With Occult Lymph Node.
- Sulin Wu – OA01.03: Uncovering Hidden Risk: The Role of Family History in Lung Cancer Among Women and Low-Exposure Smokers.
- Stephen Liu – OA01.02: Efficacy and safety of zenocutuzumab, a HER2/HER3 bispecific antibody, in treatment-naive, advanced NRG1+ NSCLC: Updated analysis from the ongoing phase 2 eNRGy trial.
The IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
IASLC designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Share
Participants
Robert Hsu
MD
Medical Oncologist
University of Southern California
Antoinette Wozniak
MD
Committee Member
Lung Cancer Research Foundation/University of Pittsburgh Hillman Cancer Center
Stephen Liu
MD
Committee Member
Georgetown University
Sulin Wu
MD, PhD, ABMGG Diplomate
Fellow, Section of Hematology and Oncology
University of Chicago Medicine Comprehensive Cancer Center
Hari Keshava
MD
Assistant Professor, Division of Thoracic Surgery
UCI Health